Empirica Therapeutics part of OBIO 2019 Capital Access Advisory Program

By CCAB - April 3, 2019 4:40 pm (leave your thoughts)

Illustration of T cells attacking cancer cells

Immune system T cells attacking cancer cells

 

Today the Ontario Bioscience Innovation Organization (OBIO) announced its 2019 Capital Access Advisory Program (CAAP) and the health science companies in this year’s program. Included in this year’s program is CCAB partner Empirica Therapeutics.

CAAP is designed to support “high-potential” Ontario companies to drive fundraising and lead to business and job growth. Read the detailed announcement.


Leave a Reply